1 2

BPC-157 & TB-500

BPC-157 & TB-500

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$99.00
$120.00 $99.00
Sale Sold out
Shipping calculated at checkout.
Quantity

BPC-157 + TB-500 — Research Blend (Barrier Peptide + Thymosin-β4 Fragment)

This blended mix combines BPC-157 (a gastric “Body Protection Compound” fragment) with a research fragment of Thymosin-β4 (TB-500). It’s designed for laboratories studying cell migration, cytoskeleton dynamics, ECM remodeling, angiogenic signaling, and barrier integrity in tissue models.

Component A — BPC-157
  • CAS: 137525-51-0
  • Sequence (15 aa): GEPPPGKPADDAGLV
  • Notes: Synthetic fragment derived from a gastric protein; used to explore barrier support, angiogenic cues, and cell migration in vitro/in vivo models.
Component B — TB-500 (Thymosin-β4 fragment)
  • Parent protein: Thymosin-β4 (Tβ4, 43 aa)
  • Fragment: Research-grade Tβ4-derived sequence (TB-500); focuses on actin binding/motility and cell migration pathways.
  • Notes: Often studied for effects on cytoskeleton reorganization, angiogenesis markers, and matrix remodeling.
Blend Rationale (Plain English)
  • BPC-157 is frequently used for barrier/ECM context (endothelium, epithelium, tendon/ligament models) and signaling that supports migration & angiogenic cues.
  • TB-500 brings complementary actin-motility biology and cell-movement dynamics, useful in wound-closure and sprouting assays.
  • Together, the blend allows labs to test ECM + motility + angiogenic endpoints in a single protocol, with options to vary ratios for mechanism mapping.

Potential Research Applications

Cell Migration & Motility

  • Scratch (“wound-healing”) assays and live-cell tracking
  • Actin polymerization / focal adhesion markers

ECM & Barrier Integrity

  • Trans-epithelial electrical resistance (TEER)
  • Collagen I/III, laminin, and MMP/TIMP panels

Angiogenesis Panels

  • Tubulogenesis, sprouting, and VEGF-pathway readouts
  • Pericyte–endothelial co-culture systems

Blend Options (Research Configurations)

Standard

  • 1:1 mass ratio (BPC:TB)
  • Balanced ECM + motility coverage

ECM-Forward

  • 2:1 (BPC-heavy)
  • Emphasis on barrier metrics and collagen markers

Motility-Forward

  • 1:2 (TB-heavy)
  • Emphasis on actin dynamics and migration speed

Design Notes

  • Pre-define primary endpoints (migration rate, TEER change, tubule length).
  • Specify salt form and end-groups (e.g., acetate, amidation) on each component in your methods.
  • Document vehicle (pH, ionic strength) — ECM and cytoskeletal readouts are condition-sensitive.

Key Study Themes (Educational Summary)

BPC-157 — barrier & ECM signaling
  • Frequently reported to influence endothelial/epithelial integrity and angiogenic cues in preclinical models.
  • Common endpoints: TEER, tight-junction proteins, collagen expression, and in vitro tubulogenesis.
TB-500 — actin & motility biology
  • Derived from Tβ4 research; used to study G-actin binding, cell motility, and sprouting in migration assays.
  • Common endpoints: wound-closure rate, actin staining, focal-adhesion proteins, and angiogenic sprout length.

Synergistic Peptides (for Study Design)

GHK-Cu

  • Why pair: ECM/trophic gene programs; complements collagen/repair markers.
  • Angle: Matrix + angiogenesis arrays with imaging of collagen deposition.

LL-37

  • Why pair: Epithelial defense and wound-closure context to round out barrier biology.
  • Angle: Co-culture wound models with cytokine readouts.

Tα1 (Thymosin-α1)

  • Why pair: Immune-context studies (innate→adaptive) alongside ECM/motility endpoints.
  • Angle: Cytokine panels + barrier integrity under challenge.

Controls

  • Include vehicle-only and single-agent arms to separate blend effects.
  • Add timing (co- vs post-challenge) and dose-response curves for mechanism clarity.

Known Concerns (Context)

  • Co-formulation: Verify compatibility (pH, buffer salts, preservatives) before blending; avoid unnecessary excipients that can confound cell assays.
  • Stability: Prepare fresh aliquots; minimize freeze–thaw cycles; protect from light/moisture.
  • Model variability: Migration/ECM endpoints can vary with serum lots, substrate coatings, and cell passage number — document conditions tightly.
  • General: For laboratory research use only; not for human consumption or therapeutic use.

Specifications & Handling

  • Form: Lyophilized powders blended to order (lot-coded)
  • Purity (each component): ≥ 99% (HPLC/MS verified)
  • Storage: ≤ −20 °C; dry, low-light conditions
  • In solution: Use sterile diluent; record pH/vehicle; aliquot immediately; avoid repeat freeze–thaw
  • Packaging: Tamper-evident; research-only labeling; blend ratio indicated on label

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

BPC-157 + TB-500 Research Blend | Barrier Integrity, Actin-Motility & Angiogenesis | ECM & Wound-Model Studies

Keywords: BPC-157, TB-500, Thymosin beta-4 fragment, cell migration, angiogenesis, ECM remodeling, wound-healing assay, Base Peptides blend.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.
Keep Shopping